hospital covid-19 Ventilators patient

New COVID studies: Remdesivir yes, hydroxychloroquine no

Reading now: 800
www.cidrap.umn.edu

The New England Journal of Medicine (NEJM) yesterday published the results of two randomized, controlled trials on two medications for the treatment of COVID-19, one supporting previous studies that found that Gilead Sciences' antiviral drug remdesivir helps patients recover faster and one adding to mounting evidence that the antimalarial drug hydroxychloroquine is no better than a placebo at preventing death in hospital patients.Faster recovery, fewer interventions for remdesivirThe first study, by the Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group, randomly assigned 1,062 hospitalized COVID-19 patients with lower respiratory tract infections to receive either a placebo or 200 milligrams (mg) of intravenous remdesivir followed by

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA